GeneLink BioSciences, Inc. Appoints Experts to its Medical Advisory Board
March 3, 2004

MARGATE, NJ, March 3, 2004 - GeneLink BioSciences, Inc. (OTCBB:GNLK), the biosciences company and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products, announced that it has appointed JAMES W. SIMPKINS, Ph.D., the Chair of the Department of Pharmacology and Neuroscience and Director, Institute for Aging and Alzheimer's Disease Research at the University of North Texas Health Science Center to head GNLK's Medical Advisory Board. GeneLink further announced that DONALD J. CANNON, Ph.D., FACB, formerly of Quest Diagnostics, has joined GNLK's prestigious Board as a scientific advisor.

James W. Simpkins received his B.S. and M.S. degrees from the University of Toledo and in 1977 received a Ph.D. Degree in Physiology from Michigan State University. He joined the faculty at the University of Florida, College of Pharmacy in 1997 and rose through the ranks to the position of Professor of Pharmacodynamics. He has served as Chairman of the Department of Pharmacodynamics, Chairman of the Department of Pharmaceuticals, Associate Dean for Research and Graduate Studies and Director, Center for Neurobiology of Aging at the University of Florida. In 1996, Dr. Simpkins was appointed as the Frank Duckworth Professor of Drug Discovery at the University of Florida. He has more than 250 peer reviewed publications, a dozen patents for his discoveries and has edited two texts on Alzheimer's disease therapy. Dr. Simpkins also served as the Director of the University of Florida Drug Discovery Group for Alzheimer's disease, which has sustained funding by the National Institute on Aging to support research in the pharmacotherapy for Alzheimer's disease. In 1999 he was appointed to the Medical and Scientific Advisory Council of the National Alzheimer's Association.

Donald J. Cannon received his A.B. in Chemistry from Harvard College, his M.A. in Medical Sciences and a Ph.D. in Biochemistry from Boston University. He was awarded pre- and postdoctoral fellowships from the National Institutes of Health. His career includes researcher, faculty member (Biochemistry and Pathology) and clinical laboratory director. He has been on the faculty at Medical Schools at the University of Hawaii, University of Arkansas, and Marshall University where he has lectured to medical, graduate, nursing and allied health students, and was director of the Pathology residency program at Marshall University. He has directed laboratories and performed research at the Boston Biomedical Research Institute, the Little Rock Arkansas VAMC and the Bethesda Hospitals in Cincinnati. He has served as Laboratory Director in Forensic Toxicology, National Manager of Operations Excellence and National Manager of Special Projects in Business Ventures at Quest Diagnostics. Dr. Cannon has over 130 publications and book chapters, and is an active member of the American Association of Clinical Scientists and the National Academy of Clinical Biochemistry.

"We are very excited to have such remarkable experts join our team. As we begin to internationally market products using our Dermagenetics™ & Nutragenetic Profiles, Drs. Simpkins and Cannon will play lead roles in development of tests and products, based on their expertise," says John DePhillipo, GeneLink's CEO.

About GeneLink: GeneLink BioSciences, Inc., since 1994, developed the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. The company is a pioneer and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products. The company both markets and licenses its proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries. For more information about GeneLink, visit its Web site at www.genelink.info.

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE: GeneLink BioSciences, Inc.